AmgenvsCryoPort

AMGN and CYRX stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$457.93

Value $247B

-0.95%
AMGN's page

Amgen (AMGN) has a market value of $247B and CryoPort (CYRX) $984M. Over the last year, with dividends, AMGN moved +39.7% and CYRX +127.7%. Dividend yield: AMGN 2.17%, CYRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$247B

    CYRX$984M

    AMGN is 251 times CYRX

  • Revenue, 12 months

    AMGN$38.9B

    CYRX$192M

    AMGN is 202 times CYRX

  • Net income, 12 months

    AMGN$9.4B

    CYRX-$41M

  • Operating margin

    AMGN32.4%

    CYRX-20.0%

    52.4 points apart

  • ROIC

    AMGN16.2%

    CYRX-4.7%

    20.9 points apart

  • P/E

    AMGN26.3

    CYRX–

  • Dividend yield

    AMGN2.2%

    CYRX0.0%

    2.2 points apart

  • 5-year return

    AMGN+158.3%

    CYRX-75.0%

    233.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+158.3%

CYRX-75.0%

010020020222023202420252026
Returns by period
PeriodAMGNWith dividendsCYRXWith dividends
1 year since November 14, 2025+39.7%Price +36.0%+127.7%Price +127.7%
3 years since November 17, 2023+87.3%+23.3% a yearPrice +72.5%+44.9%+13.2% a yearPrice +44.9%
5 years since November 16, 2021+158.3%+20.9% a yearPrice +123.0%-75.0%-24.2% a yearPrice -75.0%
10 years since November 17, 2016+315.7%+15.3% a yearPrice +210.8%+674.1%+22.7% a yearPrice +674.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenCYRXCryoPort

Valuation

AMGNCYRX
Valuation
Price$457.93$19.74
Market value$247B$984M
Enterprise value (EV)$288B$779M
P/E26.3–
P/E, 5-year median23.0–
P/B17.22.0
EV/EBIT22.8–
Free cash flow yield3.9%–

Results and growth

AMGNCYRX
Results and growth
Revenue, 12 months$38.9B$192M
Net income, 12 months$9.4B-$41M
Free cash flow, 12 months$9.6B-$19M
Earnings per share, 12 months$17.25-$0.98
Revenue growth, year on year10.0%12.4%
Revenue growth a year, past+7.6%over 5 years+17.5%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNCYRX
Margins and returns on capital
Gross margin70.9%46.9%
Operating margin32.4%-20.0%
Net margin24.1%-21.5%
ROIC16.2%-4.7%
ROE87.8%-8.3%

Balance sheet

AMGNCYRX
Balance sheet
Cash$13.2B$393M
Total debt$54.0B$231M
Net debt / EBITDA2.3–
Interest cover4.8×-18.3×

Dividends and buybacks

AMGNCYRX
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield–1.0%
Shareholder yield2.2%1.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or CYRX

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or CryoPort?

By market value, Amgen ($247B) is about 250.8 times CryoPort ($984M), at today's prices.

How did AMGN and CYRX stock do over the last 10 years?

Since November 17, 2016, AMGN's price moved +210.8% and CYRX's +674.1%. With dividends: AMGN +315.7% (+15.3% a year), CYRX +674.1% (+22.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or CYRX?

The dividend yield at today's price is 2.17% for Amgen and none for CryoPort. Over the last twelve months they paid $9.94 and – per share.

Which has the higher profit margins, Amgen or CryoPort?

Over the last twelve months, the net margin was 24.1% for Amgen and -21.5% for CryoPort, and the operating margin 32.4% and -20.0%. Revenue was $38.9B and $192M.

Which is the better investment, Amgen or CryoPort?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.